Accession Number:

ADA229090

Title:

Evaluation of Liposome-Encapsulated Hemoglobin/LR16 Formulation as a Potential Blood Substitute.

Descriptive Note:

Final rept.,

Corporate Author:

CITY OF HOPE NATIONAL MEDICAL CENTER DUARTE CA

Personal Author(s):

Report Date:

1990-01-01

Pagination or Media Count:

9.0

Abstract:

Reducing the oxygen affinity of liposome-encapsulated hemoglobin LEH to a physiologically useful range is a key step in the development of an LEH product that may potentially be used as a blood replacement fluid. Our approach to this challenge is a pharmacological one, that being the development of drug molecules capable of lowering the oxygen affinity of purified hemoglobin. In our initial proposal, we presented data which demonstrated the ability of the phenylureido-substituted phenoxyisobutyric acid compound LR16 to effectively modulate the oxygen affinity of purified human hemoglobin microencapsulated in lipid vesicles. For the surrogate blood application, LR16 appears to be of greater utility than hemoglobins natural effector molecule 2, 3-bisphosphoglycerate DPG because the latter compound undergoes fairly rapid hydrolysis during storage, thereby adversely affecting the integrity of the product.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE